Silvia Marconi

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.

Journal: Expert opinion on pharmacotherapy
Published: July 23, 2026

Anthracyclines effect on mitochondrial function and biogenesis in normal blood cells of hodgkin lymphoma patients.

Anthracyclines effect on mitochondrial function and biogenesis in normal blood cells of hodgkin lymphoma patients.

Journal: Scientific reports
Published: October 11, 2025

New insight in early detection and precision medicine in small cell lung cancer: liquid biopsy as innovative clinical tool.

New insight in early detection and precision medicine in small cell lung cancer: liquid biopsy as innovative clinical tool.

Journal: Critical reviews in clinical laboratory sciences
Published: May 26, 2025

Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives.

Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives.

Journal: Cancers
Published: January 13, 2025

Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors.

Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors.

Journal: Expert opinion on pharmacotherapy
Published: June 27, 2024

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.

Journal: Clinical and experimental medicine
Published: April 12, 2024

Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center.

Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center.

Journal: Heliyon
Published: June 13, 2023

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Journal: Cells
Published: January 27, 2023

Platelets and their derived extracellular vesicles: The new generation of markers in non-small cell lung cancer management.

Platelets and their derived extracellular vesicles: The new generation of markers in non-small cell lung cancer management.

Journal: Drug discovery today
Published: December 29, 2022

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy.

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy.

Journal: Cancers
Published: September 14, 2022

Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives.

Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives.

Journal: Expert opinion on biological therapy
Published: August 22, 2022

A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients.

A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients.

Journal: Cancers
Published: March 24, 2022
Showing 1-12 of 12

Last Updated: 09/26/2026